SAN DIEGO, Nov. 15, 2017 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies will
participate in two upcoming investor conferences.
Dr. Helen Torley, president and
chief executive officer will represent Halozyme in a question and
answer session at the 29th Annual Piper Jaffray
Healthcare Conference in New York
on Wednesday, November 29 at
8:00 a.m. ET / 5:00 a.m. PT.
On Thursday, December 14,
Jim Mazzola, vice president
corporate communication and investor relations will present a
company overview at the BMO Capital Markets 2017 Prescriptions for
Success Healthcare Conference in New
York at 3:30 p.m. ET /
12:30 p.m. PT.
Webcasts of both sessions can be accessed through the
"Investors" section of www.halozyme.com, and a recording will be
made available for 90 days following each event. To access a live
webcast, please visit Halozyme's website approximately 15 minutes
prior to the presentation to register and download any necessary
audio software.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly and Bristol-Myers
Squibb for its ENHANZE® drug delivery technology.
Halozyme is headquartered in San
Diego. For more information visit www.halozyme.com.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-participate-in-upcoming-healthcare-conferences-300555815.html
SOURCE Halozyme Therapeutics, Inc.